Megakaryocyte biology and related disorders
Liyan Pang, … , Mitchell J. Weiss, Mortimer Poncz
Liyan Pang, … , Mitchell J. Weiss, Mortimer Poncz
Published December 1, 2005
Citation Information: J Clin Invest. 2005;115(12):3332-3338. https://doi.org/10.1172/JCI26720.
View: Text | PDF
Review Series Article has an altmetric score of 9

Megakaryocyte biology and related disorders

Abstract

Platelets, derived from megakaryocytes, have an essential role in thrombosis and hemostasis. Over the past 10 years, a great deal of new information has been obtained concerning the various aspects of hematopoiesis necessary to maintain a steady-state platelet level to support physiologic hemostasis. Here we discuss the differentiation of HSCs into megakaryocytes, with emphasis on the key cytokine signaling pathways and hematopoietic transcription factors. Recent insight into these processes elucidates the molecular bases of numerous acquired and inherited hematologic disorders. It is anticipated that the growing knowledge in these areas may be exploited for new therapeutic strategies to modulate both platelet numbers and their thrombogenicity.

Authors

Liyan Pang, Mitchell J. Weiss, Mortimer Poncz

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Regulation of megakaryopoiesis by cytokines, chemokines, and transcripti...
Regulation of megakaryopoiesis by cytokines, chemokines, and transcription factors. In the middle panel, a scheme based on the classical pathway of megakaryopoiesis is shown. Cytokines and chemokines that influence that process are shown on the right side as green arrows to indicate the approximate level of development at which they have their influence. Open white areas in arrows indicate levels at which the cytokine is not known to act. Blue text refers to cytokine receptors of significance in megakaryopoiesis. Transcription factors that affect megakaryopoiesis are shown on the left side, and the lilac-colored arrows indicate the approximate point of their influence. Open white areas in arrows indicate levels at which the transcription factor is not known to act. Clinically relevant diseases linked to defects of these regulators are noted in red, italicized text. CFU-GEMM, CFU, granulocyte, erythrocyte, macrophage, megakaryocyte; CFU-EM, CFU, erythrocyte, megakaryocyte; BFU-EM, burst-forming unit, erythrocyte, megakaryocyte; CFU-Meg, CFU, megakaryocyte.